Isthmus Partners, LLC Castle Biosciences Inc Transaction History

Isthmus Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$11.66 - $26.0 $572,855 - $1.28 Million	-49,130 Reduced 76.2%	15,342 $210,000
Q1 2023 May 10, 2023	BUY	$19.47 - $28.49 $129,670 - $189,743	6,660 Added 11.52%	64,472 $1.46 Million
Q4 2022 Feb 10, 2023	BUY	$18.08 - $30.0 $21,207 - $35,190	1,173 Added 2.07%	57,812 $1.36 Million
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $88,351 - $134,706	3,925 Added 7.45%	56,639 $1.48 Million
Q2 2022 Aug 08, 2022	BUY	$16.0 - $45.99 $199,856 - $574,461	12,491 Added 31.05%	52,714 $1.16 Million
Q1 2022 May 04, 2022	BUY	$33.17 - $46.98 $80,072 - $113,409	2,414 Added 6.38%	40,223 $1.8 Million
Q4 2021 Jan 25, 2022	BUY	$39.06 - $67.58 $1.1 Million - $1.91 Million	28,247 Added 295.41%	37,809 $1.62 Million
Q3 2021 Nov 10, 2021	SELL	$60.13 - $77.6 $901 - $1,164	-15 Reduced 0.16%	9,562 $636,000
Q2 2021 Aug 10, 2021	BUY	$50.07 - $76.78 $479,520 - $735,322	9,577 New	9,577 $702,000

201

24.5M

303K

30.3K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $656M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Isthmus Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Isthmus Partners, LLC with notifications on news.